Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03355573 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis
A Phase 2 study, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 2
- Development phase
- 255
- Enrollment target
NCT03355573 is a Phase 2 study that has completed, run by UCB Biopharma SRL. The registered enrollment target is 255 participants.
The verdict
NCT03355573, a Phase 2 study, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 255 participants
- Enrollment target
Study Summary
This is a study to assess the long term safety and tolerability of bimekizumab in subjects with ankylosing spondylitis
Interventions
- DRUG Bimekizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2017-11-28 |
| Est. Completion | 2022-10-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03355573
The ClinicalTrials.gov registry entry for NCT03355573 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bimekizumab is the first listed.
NCT03355573 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03355573 about?
NCT03355573 is a clinical study titled "A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis". This is a study to assess the long term safety and tolerability of bimekizumab in subjects with ankylosing spondylitis
What is the current status of trial NCT03355573?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 255 participants. The study started on 2017-11-28. Estimated completion is 2022-10-19.
What interventions are being tested in trial NCT03355573?
The interventions under investigation include: Bimekizumab (DRUG).
Who is sponsoring clinical trial NCT03355573?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.